Key Insights

Highlights

Success Rate

75% trial completion

Published Results

33 trials with published results (13%)

Research Maturity

83 completed trials (34% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.4%

28 terminated out of 246 trials

Success Rate

74.8%

-11.8% vs benchmark

Late-Stage Pipeline

4%

9 trials in Phase 3/4

Results Transparency

40%

33 of 83 completed with results

Key Signals

33 with results75% success28 terminated

Data Visualizations

Phase Distribution

190Total
Not Applicable (21)
Early P 1 (7)
P 1 (79)
P 2 (74)
P 3 (8)
P 4 (1)

Trial Status

Completed83
Recruiting60
Unknown36
Terminated28
Active Not Recruiting20
Not Yet Recruiting10

Trial Success Rate

74.8%

Benchmark: 86.5%

Based on 83 completed trials

Clinical Trials (246)

Showing 20 of 20 trials
NCT07628634Early Phase 1Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT04616560Phase 1Recruiting

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

NCT03628209Phase 1Active Not RecruitingPrimary

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

NCT05227326Phase 1Recruiting

AOH1996 for the Treatment of Refractory Solid Tumors

NCT04040205Phase 2Recruiting

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

NCT07725380Phase 1Recruiting

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

NCT02867592Phase 2Active Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT03006848Phase 2CompletedPrimary

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

NCT07321912Phase 2RecruitingPrimary

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

NCT03960177Early Phase 1CompletedPrimary

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

NCT07514819Not ApplicableNot Yet Recruiting

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

NCT06541262Phase 1Recruiting

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

NCT06465199Phase 1Recruiting

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

NCT06625190Phase 1Recruiting

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT00840047Phase 2Active Not Recruiting

Methionine PET/CT Studies In Patients With Cancer

NCT07648069Phase 1Recruiting

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

NCT03900793Phase 1RecruitingPrimary

Losartan + Sunitinib in Treatment of Osteosarcoma

NCT06235125Phase 1RecruitingPrimary

Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

NCT07129226Not ApplicableRecruitingPrimary

Musculoskeletal Cancers Remote Monitoring and Care

NCT06492954Phase 1RecruitingPrimary

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Scroll to load more

Research Network

Activity Timeline